Portfolio company MapLight Therapeutics completed its IPO in October 2025.
A clinical-stage biopharma company based in California, focused on therapies for CNS disorders
A clinical-stage biopharma company based in California, focused on therapies for CNS disorders. The company employs proprietary technologies including optogenetics, STARmap and transcriptomics to inform drug discovery and candidate selection.